List of Excipients in Branded Drug CLOZAPINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals USA Inc	CLOZAPINE	clozapine	0093-3011	ASPARTAME
Teva Pharmaceuticals USA Inc	CLOZAPINE	clozapine	0093-3011	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	CLOZAPINE	clozapine	0093-3011	CITRIC ACID MONOHYDRATE
Teva Pharmaceuticals USA Inc	CLOZAPINE	clozapine	0093-3011	CROSPOVIDONE
Teva Pharmaceuticals USA Inc	CLOZAPINE	clozapine	0093-3011	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
Teva Pharmaceuticals USA Inc	CLOZAPINE	clozapine	0093-3011	FERRIC OXIDE YELLOW
Teva Pharmaceuticals USA Inc	CLOZAPINE	clozapine	0093-3011	MAGNESIUM STEARATE

Generic Drugs Containing CLOZAPINE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	clozapine	0093-4359	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	clozapine	0093-4359	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	clozapine	0093-4359	POVIDONE K90
Teva Pharmaceuticals USA Inc	clozapine	0093-4359	SILICON DIOXIDE
Teva Pharmaceuticals USA Inc	clozapine	0093-4359	STARCH, CORN
Teva Pharmaceuticals USA Inc	clozapine	0093-4359	TALC
Teva Pharmaceuticals USA Inc	clozapine	0093-5376	ASPARTAME

What are the Most Frequently-Used Excipients in CLOZAPINE?

# Of NDCs	Excipient
7	ASPARTAME
7	CELLULOSE, MICROCRYSTALLINE
10	CROSPOVIDONE
3	FD&C RED NO. 40
4	FD&C YELLOW NO. 6
1	FERRIC OXIDE YELLOW
12	LACTOSE

Clozapine Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Clozapine is a mature generic antipsychotic with limited protection from core drug patents and substantial commercial room in differentiated oral formulations. The strongest opportunities are orally disintegrating tablets, ready-to-use oral suspensions, taste-masked liquids, sprinkle products, and tube-compatible dosage forms that improve adherence without changing clozapine exposure. Regulatory value depends on bioequivalence, dose uniformity, stability, excipient safety, and reliable handling of clozapine’s mandatory blood-monitoring requirements.

What is the commercial status of clozapine?

Clozapine is an atypical antipsychotic approved for treatment-resistant schizophrenia and reduction of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. Novartis commercialized the branded product Clozaril. U.S. marketing is now dominated by generic tablets and several differentiated dosage forms.

Product or dosage form	U.S. regulatory position	Commercial relevance
Clozaril tablets	Reference product; brand availability is limited relative to generics	Historical benchmark for tablet composition
Generic clozapine tablets	Approved through ANDA pathway	Price-competitive, limited differentiation
FazaClo orally disintegrating tablets	FDA-approved ODT product; brand availability may vary	Addresses swallowing difficulty and adherence
Versacloz oral suspension	FDA-approved liquid suspension	Supports patients unable to swallow tablets and institutional use
Compounded liquid clozapine	Used in some settings under pharmacy or institutional procedures	Less standardized than an approved commercial product
Future sprinkle or tube-compatible products	Potentially approvable through an abbreviated or 505(b)(2) strategy, depending on formulation and claims	Highest formulation differentiation potential

Clozapine remains clinically important because many patients with treatment-resistant schizophrenia do not achieve adequate control with other antipsychotics. Its use is constrained by neutropenia risk, seizure risk, myocarditis concerns, constipation, sedation, hypersalivation, metabolic effects, and the operational burden of blood-count monitoring [1, 2].

The commercial opportunity is therefore less about creating a new molecule and more about reducing administration friction while preserving pharmacokinetic performance.

What patents protect clozapine?

The foundational clozapine composition-of-matter protection is expired in the United States and major European markets. Clozapine has been commercially available as a generic for decades.

The original U.S. patent commonly associated with clozapine is U.S. Patent No. 3,539,573, assigned to Wander AG. It covered clozapine and related compounds and expired long before the current generic market. No live composition patent should be assumed to block ordinary clozapine tablets.

IP category	Current commercial effect
Clozapine molecule	Foundational protection expired
Conventional immediate-release tablets	Generally open to generic competition
ODT formulations	Potential protection depends on specific composition, manufacturing process, and claim scope
Oral suspensions	Potential protection may cover physical stability, suspension systems, packaging, or dosing devices
Taste-masked formulations	Potentially protectable through polymer, coating, complexation, or multiparticulate claims
Method-of-use claims	Possible claims may target patient populations or administration methods, but enforcement value depends on claim language and clinical practice
Manufacturing processes	May protect particle size, granulation, coating, or suspension manufacture if claims are narrow and non-obvious

The principal IP risk for a new entrant is not the expired clozapine molecule. It is the possibility that a branded or specialty manufacturer holds live formulation, device, method-of-use, or manufacturing patents.

When does clozapine lose exclusivity?

Clozapine lost effective small-molecule exclusivity years ago. FDA-approved generic tablets are available, and the principal commercial barrier is no longer the active ingredient patent.

FDA listed clozapine products under the ANDA framework after expiration of the originator’s market protection. Product-specific exclusivity periods associated with later dosage forms, such as ODT or oral suspension products, do not restore broad protection to the clozapine molecule.

U.S. exclusivity timeline

Milestone	Approximate timing	Effect
Original clozapine patenting	Late 1960s to early 1970s	Created initial compound protection
Clozaril U.S. approval	1989	Established the U.S. reference product
Generic tablet entry	1990s	Removed practical monopoly for conventional tablets
FazaClo approval	2000s	Introduced an ODT differentiation strategy
Versacloz approval	2010s	Introduced an approved oral suspension
Current market	2020s	Mature generic market with formulation-based opportunities

Exact patent and exclusivity determinations require review of the current FDA Orange Book and the product-specific regulatory history. The commercial conclusion is clear: conventional clozapine tablets face established generic competition, while differentiated delivery systems remain more defensible.

What excipients are used in clozapine products?

Clozapine products use conventional tablet excipients, but the choice of excipient can influence disintegration, dissolution, taste, stability, manufacturability, and patient acceptance.

Typical excipient classes include:

Excipient class	Examples used or potentially useful in clozapine	Strategic function
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol	Tablet mass, compressibility, mouthfeel
Superdisintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup
Binder	Povidone, hydroxypropyl cellulose	Granule strength and content uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and manufacturing control
Glidant	Colloidal silicon dioxide	Powder flow
Film former	Hypromellose	Appearance, handling, moisture barrier
Sweetener	Aspartame, sucralose, acesulfame potassium	Taste masking
Polyol	Mannitol, sorbitol, xylitol	ODT bulk and cooling mouthfeel
Suspending agent	Xanthan gum, cellulose derivatives	Physical stability in liquids
Preservative	Sodium benzoate or other permitted systems	Microbial control in aqueous products
Flavor	Mint, fruit, vanilla, or other compatible flavors	Palatability
Wetting agent	Polysorbates or other surfactants	Dispersion and dissolution

The marketed reference and specialty products do not establish a universal excipient formula. Generic applicants can use different inactive ingredients if the formulation satisfies FDA requirements for quality, labeling, safety, and bioequivalence.

Excipient constraints specific to clozapine

Clozapine requires tighter formulation control than many routine psychiatric medicines.

First, the active dose is relatively small compared with tablet mass. Content uniformity and segregation control are therefore important, particularly for direct-compression formulations.

Second, clozapine is vulnerable to formulation changes that affect dissolution. A formulation that disintegrates rapidly but produces altered dissolution across pH conditions may create a regulatory or clinical problem.

Third, patients may take clozapine for years. Chronic exposure favors conservative excipient selection, low impurity profiles, robust supplier qualification, and minimal use of excipients associated with gastrointestinal intolerance.

Fourth, many patients have dysphagia, hypersalivation, constipation, cognitive impairment, or poor adherence. An excipient strategy should be designed around these clinical conditions rather than around tablet cost alone.

What formulations are protected or commercially differentiated for clozapine?

Orally disintegrating tablets

ODTs are the most direct opportunity for excipient-driven differentiation. A clozapine ODT can use mannitol or another polyol for mouthfeel, crospovidone or croscarmellose for rapid disintegration, and a taste-masking system based on sweeteners, flavors, coating, or polymeric protection.

The formulation target should be rapid disintegration without premature drug release in the mouth. Clozapine has a bitter taste, so simply increasing sweetener concentration may be inadequate.

Potential claim categories include:

• Specific clozapine-to-mannitol ratios
• Superdisintegrant combinations
• Taste-masked particles
• Low-friability ODT architecture
• Moisture-resistant packaging
• Manufacturing processes that improve content uniformity
• Defined disintegration or dissolution profiles

ODTs are attractive for patients who resist or cannot swallow conventional tablets. Their weakness is commercial substitution pressure if generic tablets remain significantly cheaper and caregivers can administer them successfully.

Ready-to-use oral suspension

An oral suspension can target patients with severe swallowing limitations, feeding tubes, or institutional administration requirements. Its technical challenges are greater than those of a tablet.

A viable suspension must control:

• Sedimentation and redispersibility
• Dose uniformity throughout the bottle
• Chemical stability
• Microbial growth
• Adsorption to containers or feeding tubes
• Syringe and measuring-device accuracy
• Flavor and mouthfeel
• Storage conditions after opening

Suspension claims may be more defensible than ordinary tablet claims when they cover a specific stabilizer system, particle-size distribution, preservative combination, packaging configuration, or stability profile. The product must still demonstrate that the delivery system does not create clinically meaningful exposure differences.

Taste-masked liquid

Taste masking is a high-value feature because clozapine’s bitterness can reduce acceptance, particularly in patients with cognitive impairment or when caregivers administer liquid medicine.

Potential technologies include:

• Polymer-coated clozapine particles
• Ion-exchange resin complexes
• Lipid or wax matrices
• Cyclodextrin complexes
• Multiparticulates suspended in a flavored vehicle
• pH-controlled release systems

The best commercial design would mask bitterness during oral contact while releasing clozapine rapidly after swallowing. A formulation that delays or incompletely releases the drug risks bioequivalence failure.

Sprinkle and feeding-tube dosage forms

A sprinkle formulation could allow administration over soft food without requiring a patient to swallow a tablet. A tube-compatible product could serve long-term-care facilities and psychiatric hospitals.

The primary technical risks are dose loss, tube adsorption, clogging, interaction with enteral nutrition, and incomplete delivery after flushing. These products require in vitro administration studies using clinically relevant tubes, flush volumes, and food vehicles.

Such products may qualify for stronger differentiation because the administration method, packaging, dose preparation, and device instructions can be claimed together.

How strong is the patent estate for clozapine formulations?

The clozapine patent estate is strong for the molecule only in a historical sense. It is weak for ordinary tablets because the market has long supported generic substitution. It can be moderate for a well-engineered specialty formulation if the claims are narrow but technically difficult to design around.

Product concept	Patent strength	Regulatory complexity	Commercial potential
Standard immediate-release tablet	Low	Low to moderate	Low margin, high volume
Conventional ODT	Low to moderate	Moderate	Moderate
Taste-masked ODT	Moderate	Moderate to high	High in adherence-focused segments
Ready-to-use suspension	Moderate	High	High for institutions and dysphagia
Sprinkle formulation	Moderate to high	High	Moderate to high
Tube-compatible formulation	Moderate to high	High	Niche but defensible
Long-acting injectable clozapine	Potentially high	Very high	Uncertain development risk
Abuse-deterrent or modified-release clozapine	Potentially high	High	Limited clinical rationale

Patent strength depends on the number of independent claim elements that a competitor must replicate. A narrow claim directed to a specific excipient ratio is often easier to design around than a platform claim covering a broad class of taste-masking systems. Manufacturing claims can strengthen the estate when the process materially improves stability or dose uniformity.

What is the FDA regulatory status of clozapine?

Clozapine is an FDA-approved prescription drug subject to special safety controls. The FDA’s Clozapine REMS program was established to manage neutropenia risk through absolute neutrophil count monitoring. The FDA removed the mandatory REMS program in 2022, but prescribers and pharmacies remain responsible for evaluating neutropenia risk and monitoring patients under the agency’s modified framework [3].

A new clozapine dosage form must address more than ordinary ANDA requirements.

Regulatory routes

An ANDA may be available when the proposed product has the same active ingredient, dosage form, strength, route, conditions of use, and labeling framework as the reference product, with demonstrated bioequivalence.

A 505(b)(2) application may be more appropriate when the product introduces a clinically meaningful dosage-form change, a new administration method, or reliance on some published or FDA-held data while requiring additional studies.

Regulatory strategy should be determined by the intended claims:

Development objective	Likely regulatory logic
Low-cost tablet generic	ANDA
Conventional ODT equivalent	ANDA may be possible
New taste-masking technology	ANDA or 505(b)(2), depending on formulation and labeling
Ready-to-use suspension with differentiated use	ANDA or 505(b)(2)
New dosing device or administration method	505(b)(2) risk increases
New indication or patient population	505(b)(2) or supplemental NDA
Long-acting injectable	New drug development pathway

FDA guidance on orally disintegrating tablets emphasizes disintegration, mechanical strength, packaging, and patient usability. Suspension products require control of particle size, redispersibility, dose uniformity, microbiological quality, and stability [4, 5].

What generic entry risks exist for clozapine?

Generic entry risk is high for conventional tablets and lower for differentiated dosage forms.

Paragraph IV challenges

A Paragraph IV certification could target live patents listed for a branded ODT, suspension, method of use, or manufacturing process. The challenge would need to show that the patent is invalid, unenforceable, or not infringed.

For a conventional tablet, the risk is more likely to involve routine ANDA competition than a major Paragraph IV campaign. For a specialty product, a generic applicant may challenge:

• Composition claims covering the excipient system
• Particle-coating or taste-masking claims
• Suspension-stability claims
• Packaging or dosing-device claims
• Method-of-use claims directed to administration in patients with swallowing impairment

The economic value of a Paragraph IV challenge is limited if the specialty product has low sales. Litigation may still be rational when the formulation has institutional contracts or a large long-term-care channel.

Generic launch scenarios

Scenario	Likely market effect
Additional standard tablets	Price erosion and pharmacy substitution
Generic ODT	Pressure on branded ODT pricing
Generic suspension	Lower institutional acquisition cost
New sprinkle product	May expand use rather than directly replace tablets
Multiple taste-masked products	Rapid differentiation erosion unless supported by device, service, or supply advantages

Which companies are positioned in the clozapine market?

The market has historically included Novartis through Clozaril, specialty manufacturers associated with FazaClo and Versacloz, and multiple generic suppliers. The active competitive field can change through discontinuations, shortages, acquisitions, and supply agreements.

Commercial diligence should track:

• FDA Drugs@FDA approvals
• FDA Orange Book listings
• FDA drug shortage records
• DailyMed labeling
• National drug code activity
• Medicaid and hospital contract participation
• REMS and monitoring-service infrastructure
• Manufacturing-site reliability

The most defensible entrant is unlikely to win solely through a lower tablet price. A formulation company can compete through reliable supply, integrated ANC-monitoring support, accurate dosing devices, institutional packaging, and reduced administration burden.

What licensing deals and partnerships matter for clozapine?

Clozapine licensing opportunities are more likely to involve formulation technology, manufacturing, or distribution than molecule rights.

Potential transaction structures include:

1. A specialty pharmaceutical company licenses an ODT or taste-masking platform to a generic manufacturer.
2. A contract development and manufacturing organization supplies a ready-to-use suspension under a commercial license.
3. A drug-delivery company licenses tube-compatible multiparticulates.
4. A manufacturer acquires regional rights for an approved dosage form.
5. A monitoring or specialty-pharmacy provider bundles medication supply with adherence and laboratory coordination.

The most valuable assets are products with FDA approval, demonstrated stability, low manufacturing complexity, and a clear payer or institutional use case. A patent application without clinical or regulatory validation has limited licensing value in a mature generic market.

How does clozapine compare with competing antipsychotics?

Clozapine has a distinctive commercial position. Other atypical antipsychotics generally have larger patient populations and broader dosage-form portfolios, but clozapine has a high unmet-need segment among treatment-resistant patients.

Attribute	Clozapine	Aripiprazole	Olanzapine	Risperidone
Primary differentiated need	Treatment resistance and suicidality	Broad use and long-acting therapy	Efficacy with metabolic trade-offs	Broad oral and long-acting options
Monitoring burden	High	Low relative burden	Lower	Lower
Liquid or ODT opportunity	Meaningful	Competitive	Competitive	Competitive
Generic price pressure	High	High	High	High
Adherence barrier	Administration plus blood monitoring	Administration and persistence	Sedation and metabolic effects	Adverse effects and persistence
Biosimilar risk	None	None	None	None

Clozapine’s monitoring burden can reduce prescribing even when clinically appropriate. A better dosage form can address administration problems but cannot eliminate hematologic monitoring or other safety obligations.

What is the revenue exposure and commercial opportunity?

Clozapine is a mature, lower-price market, so revenue depends on volume, channel access, and product differentiation. Standard tablets are vulnerable to price competition and wholesaler substitution. Specialty formulations can support higher pricing when they reduce care complexity.

The most attractive segments are:

• Psychiatric hospitals
• Long-term-care facilities
• Patients with dysphagia
• Patients receiving medication through enteral tubes
• Caregivers administering medication
• Patients with poor adherence to conventional tablets
• Health systems seeking standardized liquid dosing
• Markets with clozapine supply interruptions

A commercial model can combine the dosage form with packaging, dosing syringes, institutional protocols, and specialty distribution. The product should be priced against the total administration cost, not only the tablet acquisition price.

What manufacturing and geographic barriers affect clozapine?

Clozapine manufacture is technically established, but specialty formulations introduce new barriers:

• Low-dose content uniformity
• Control of polymorphic or particle-size variation
• Moisture sensitivity in ODT packaging
• Suspension redispersibility
• Preservative efficacy
• Compatibility with oral syringes and feeding tubes
• Validated cleaning procedures for potent pharmaceutical handling
• Reliable supply of pharmaceutical-grade flavoring and masking materials
• Stability across hot and humid markets

Geographic expansion requires review of local requirements for clozapine monitoring, prescription controls, import registration, excipient permissions, and pharmacovigilance. A formulation accepted in the United States may require separate bioequivalence, stability, or device data in Europe, Japan, China, or emerging markets.

Key Takeaways

• Clozapine’s core composition-of-matter protection is expired, and conventional tablets are exposed to generic competition.
• The highest-value opportunities are ODTs, taste-masked liquids, ready-to-use suspensions, sprinkle products, and tube-compatible dosage forms.
• Excipient selection should prioritize taste, rapid disintegration, suspension stability, dose uniformity, chronic-use tolerability, and unchanged clozapine exposure.
• Formulation patents can provide moderate protection, but narrow excipient claims are vulnerable to design-around strategies.
• A new product may use an ANDA pathway, although 505(b)(2) risk increases with new administration methods, devices, indications, or clinical claims.
• Paragraph IV litigation is more relevant to branded specialty formulations than to conventional clozapine tablets.
• Biosimilar risk is not relevant because clozapine is a synthetic small molecule.
• The strongest commercial proposition combines a differentiated dosage form with reliable supply, institutional packaging, and adherence support.

FAQs

Is clozapine available as a liquid?

Yes. FDA-approved clozapine oral suspension products have been marketed, and compounded liquids may also be used in some clinical settings. Approved products offer greater standardization of concentration, stability, labeling, and dosing.

Can clozapine be formulated as an orally disintegrating tablet?

Yes. ODT products have been approved for clozapine. Commercial development should focus on taste masking, rapid disintegration, mechanical strength, moisture protection, and bioequivalence.

Which excipients are most suitable for clozapine ODTs?

Mannitol, crospovidone, croscarmellose sodium, microcrystalline cellulose, povidone, sweeteners, flavors, and moisture-protective packaging are common strategic choices. The final selection must support dissolution, stability, and patient acceptability.

Does clozapine have biosimilar competition?

No. Clozapine is a synthetic small-molecule drug. Competition arises through generic tablets and differentiated formulations, not biosimilar products.

Can a clozapine formulation patent block generic entry?

Yes, if the patent contains valid, enforceable claims covering the proposed formulation, manufacturing process, administration method, or device. A formulation patent does not automatically restore protection to the clozapine molecule or all clozapine products.

References

1. U.S. Food and Drug Administration. (2024). Clozapine prescribing information and safety communications. FDA.

2. National Institute for Health and Care Excellence. (2014, updated 2023). Psychosis and schizophrenia in adults: Prevention and management. NICE Guideline CG178.

3. U.S. Food and Drug Administration. (2022). FDA modifies REMS program for clozapine. FDA.

4. U.S. Food and Drug Administration. (2008). Guidance for industry: Orally disintegrating tablets. FDA.

5. U.S. Food and Drug Administration. (1997). SUPAC-IR: Immediate-release solid oral dosage forms. FDA.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

7. U.S. National Library of Medicine. (2024). DailyMed: Clozapine, FazaClo, Versacloz, and generic product labeling. DailyMed.

8. U.S. Patent No. 3,539,573. (1970). Dibenzodiazepine derivatives. U.S. Patent and Trademark Office.